Lineage Cell Therapeutics (LCTX) Treasury Shares (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Treasury Shares of $2.9 million for Q4 2016, down 83.97% year-over-year from $18.0 million in Q1 2016, and little changed quarter-over-quarter from $2.9 million in Q3 2016.
Lineage Cell Therapeutics (LCTX) Treasury Shares (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Treasury Shares history runs 6 years deep, the most recent figure standing at $2.9 million for Q4 2016.
- In Q4 2016, Treasury Shares fell 83.97% year-over-year to $2.9 million; the TTM figure through Dec 2016 stood at $2.9 million (down 83.97% YoY), while the FY2016 annual figure was $2.9 million, down 83.97% from the prior year.
- Treasury Shares for Q4 2016 stood at $2.9 million, roughly flat from $2.9 million in the prior quarter.
- The five-year high for Treasury Shares was $939000.0 in Q4 2022, with the low at $248000.0 in Q1 2026.
- The 5-year median for Treasury Shares is $501000.0 (2024), against an average of $494583.3.
- The sharpest annual moves came in 2013 and 2016: Treasury Shares soared 413.81% in 2013, then tumbled 85.47% in 2016.
- Lineage Cell Therapeutics' Treasury Shares stood at $8.4 million in 2012, then jumped by 413.81% to $43.0 million in 2013, then plunged by 53.78% to $19.9 million in 2014, then dropped by 9.34% to $18.0 million in 2015, then plunged by 83.97% to $2.9 million in 2016.
- Business Quant data shows LCTX's Treasury Shares at $2.9 million in Q4 2016, $2.9 million in Q3 2016, and $2.9 million in Q2 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 248,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 248,000.00 |
| Jun 30, 2026 | 248,000.00 |
| Mar 31, 2026 | 248,000.00 |
| Mar 31, 2026 | 248,000.00 |
| Dec 31, 2025 | 315,000.00 |
| Dec 31, 2025 | 315,000.00 |
| Sep 30, 2025 | 334,000.00 |
| Sep 30, 2025 | 334,000.00 |
| Jun 30, 2025 | 334,000.00 |
| Jun 30, 2025 | 334,000.00 |
| Mar 31, 2025 | 334,000.00 |
| Mar 31, 2025 | 334,000.00 |
| Dec 31, 2024 | 501,000.00 |
| Dec 31, 2024 | 501,000.00 |
| Sep 30, 2024 | 501,000.00 |
| Sep 30, 2024 | 501,000.00 |
| Jun 30, 2024 | 501,000.00 |
| Jun 30, 2024 | 501,000.00 |
| Mar 31, 2024 | 501,000.00 |
| Mar 31, 2024 | 501,000.00 |